Immunization of mice with a synthetic peptide that corresponds to a murine antibody-defined immunodominant domain of herpes simplex virus (HSV) glycoprotein D (gD) induced neutralizing antibodies against HSV types 1 and 2 and protected animals against a lethal challenge with HSV type 2 (Dietzschold, B., Eisenberg, R., Ponce de Leon, M., Golub, E., Hudecz, F., Varicchio, A. & Cohen, G. (1984) J. Virol. 52,[431][432][433][434][435]. We report here that human peripheral blood T cells from HSV-seropositive and -seronegative adult donors are activated by this synthetic peptide in vitro. Interleukin-2-dependent T-cell lines established from these cultures respond specifically to peptides containing residues 1-23 of HSV gD and to a panel of overlapping peptides within this domain. The T-cell proliferative response was maximal when the majority of interleukin-2-propagated T cells were of the helper phenotype and the peptides were at least 16 amino acids long. Peptides of 8 or 12 amino acids from the carboxyl terminus were nonstimulatory. Peptide-activated T-cell lines from seronegative donors less than 11 years old could be established in vitro, but most cells were of the suppressor/cytotoxic phenotype and demonstrated no antigen-specificity when tested with the panel of synthetic peptides.The immune response to herpes simplex virus (HSV) has been shown to involve a variety of effector mechanisms which include production of virus-neutralizing antibody, cytotoxic T lymphocytes, natural killer (NK) cells, antibodydependent cellular cytotoxicity, and T-cell-derived lymphokines (43). The pivotal role of helper T-cells in the induction of these responses has been well documented (44,45).The nature of the HSV-specified antigens that act as immunostimulants has not been completely identified, but several lines of evidence implicate the major viral glycoproteins (1). One of these, glycoprotein D (gD), has been shown to induce type-common viral-neutralizing antibody (2, 3), and passive administration of monoclonal antibody (mAb) specific for gD protects mice from a lethal challenge with HSV (4). Moreover, gD appears to be recognized on HSV-infected cells by cytolytic effector cells (5).An antibody-defined immunodominant determinant of HSV type 1 (HSV-1) gD was localized and a peptide corresponding to residues 8-23 of the mature glycoprotein was synthesized. This peptide was recognized by an anti-gD mAb known to neutralize HSV-1 and -2 (6). Moreover, immunization of mice with this synthetic molecule induces viral-neutralizing antibodies and confers protection against a lethal challenge with HSV-2 (7).
MATERIALS AND METHODSSynthesis of HSV gD Peptides. Peptides were manually synthesized as described (6) by using the Merrifield solidphase method (8). The completed peptides were simultaneously deprotected and cleaved from the resin with anhydrous HF containing thioanisole as an organic cation scavenger. The crude peptides were purified by gel filtration on Bio-Gel P-2 or P-4 (Bio-Rad) columns. Homogeneity of the peptides w...